• Molecular NameGlibenclamide
  • SynonymApo-Glibenclamide; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Glyburide
  • Weight494.012
  • Drugbank_IDDB01016
  • ACS_NO10238-21-8
  • Show 3D model
  • LogP (experiment)4.8
  • LogP (predicted, AB/LogP v2.0)4.42
  • pka5.3
  • LogD (pH=7, predicted)2.58
  • Solubility (experiment)0.004 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.43
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors3
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds8
  • TPSA121.98
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-diabetic drug in a class of medications known as sulfonylureas.
  • Absorption_value100.0
  • Absorption (description)Readily absorbed after oral administration
  • Caco_2N/A
  • Bioavailability80.0
  • Protein binding99.0
  • Volume of distribution (VD)0.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, 2.
  • Metabollsmwidely distributed throughout the body and metabolised mainly by 4-trans- and 3-cis-hydroxylation of the cyclohexyl ring.
  • Half life5~16 h
  • ExcretionAbout 20 to 50% of a dose is excreted in the urine in 24 h, mainly as metabolites; about 45 to 75% of a dose is eliminated in the faeces over a period of 5 days.
  • Urinary ExcretionNegligible
  • Clerance1.3 ml/min/kg
  • ToxicityIn a suicide attempt, a concentration of 0.6 mg/L was found in the serum initially. After 84 h the concentration had declined to <0.1 mg/L. [M. Berger et al.,Dtsch. Med. Wochenschr.,1977, 102, 586–587.]
  • LD50 (rat)LD50: > 20,000 mg/kg
  • LD50 (mouse)LD50: 3250 mg/kg